Gelesis Holdings, Inc. (GLS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gelesis Holdings, Inc. (GLS) with AI Score 61/100 (Hold). Gelesis Holdings Inc. is a commercial-stage biotherapeutics company focused on developing treatments for obesity and GI-related chronic diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Gelesis Holdings, Inc. (GLS) Healthcare & Pipeline Overview
Gelesis Holdings Inc. is a commercial-stage biotherapeutics company specializing in treatments for obesity and gastrointestinal disorders, primarily through its lead product, PLENITY. The company operates within the competitive biotechnology sector, focusing on non-systemic weight management solutions and pipeline development for related chronic diseases.
Investment Thesis
Gelesis Holdings Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead product, PLENITY, offers a novel approach to weight management, but its commercial success is still uncertain. Key value drivers include the continued adoption of PLENITY, successful development of pipeline therapies for NAFLD/NASH and type 2 diabetes, and strategic partnerships to expand market reach. The company's negative profit margin of -216.5% and negative gross margin of -7.0% highlight the financial challenges. Upcoming clinical trial results for pipeline candidates and potential regulatory approvals represent significant catalysts. However, the company faces potential risks related to competition, regulatory hurdles, and the need for additional capital to fund operations.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.20 reflects current unprofitability, common for early-stage biotechnology companies.
- Profit margin of -216.5% highlights substantial operating losses and the need for improved cost management or revenue generation.
- Gross margin of -7.0% indicates that the cost of goods sold exceeds revenue, requiring significant improvements in production or pricing strategies.
- Beta of 0.99 suggests the stock's volatility is similar to the overall market.
Competitors & Peers
Strengths
- Novel biomimicry technology platform.
- PLENITY offers a non-systemic approach to weight management.
- Pipeline of therapies targeting large and growing markets.
- Experienced management team with expertise in drug development.
Weaknesses
- Limited commercial track record.
- Negative profit and gross margins.
- High dependence on the success of PLENITY.
- Requires additional capital to fund operations.
Catalysts
- Upcoming: Clinical trial results for pipeline therapies targeting NAFLD/NASH and type 2 diabetes.
- Upcoming: Potential regulatory approvals for pipeline therapies.
- Ongoing: Expansion of PLENITY's market reach through strategic partnerships.
- Ongoing: Increasing awareness and adoption of PLENITY among healthcare providers and consumers.
Risks
- Potential: Competition from established pharmaceutical companies with greater resources.
- Potential: Regulatory hurdles and delays in clinical trial processes.
- Potential: Safety or efficacy concerns with PLENITY or pipeline therapies.
- Ongoing: Dependence on the success of PLENITY for revenue generation.
- Ongoing: Need for additional capital to fund operations and expansion.
Growth Opportunities
- Growth opportunity 1: Expanding the market reach of PLENITY through strategic partnerships with healthcare providers and direct-to-consumer marketing initiatives. The weight management market is estimated to be worth billions of dollars, and increasing awareness and accessibility of PLENITY could drive significant revenue growth. Timeline: Ongoing, with continuous efforts to expand distribution and marketing efforts.
- Growth opportunity 2: Advancing the clinical development of pipeline therapies for NAFLD/NASH and type 2 diabetes. Successful clinical trials and regulatory approvals could lead to blockbuster drugs and significant revenue streams. The market for NAFLD/NASH therapies is projected to grow rapidly in the coming years. Timeline: Ongoing, with clinical trials expected to continue over the next several years.
- Growth opportunity 3: Developing and commercializing GS500 for functional constipation. This represents an opportunity to address a common GI disorder with a novel therapeutic approach. The market for constipation treatments is substantial, and a successful product could generate significant revenue. Timeline: Ongoing, with preclinical and clinical development activities underway.
- Growth opportunity 4: Exploring potential applications of Gelesis' biomimicry technology platform in other therapeutic areas beyond obesity and GI disorders. This could lead to the development of new therapies for a range of chronic diseases. Timeline: Long-term, with ongoing research and development efforts to identify new applications.
- Growth opportunity 5: Leveraging digital health technologies to enhance patient engagement and improve treatment outcomes. This could involve developing mobile apps or wearable devices to track patient progress and provide personalized support. The digital health market is growing rapidly, and integrating these technologies could provide a competitive advantage. Timeline: Ongoing, with potential for future development and integration of digital health solutions.
Opportunities
- Expanding the market reach of PLENITY through strategic partnerships.
- Advancing the clinical development of pipeline therapies.
- Exploring new applications of the biomimicry technology platform.
- Leveraging digital health technologies to enhance patient engagement.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and lengthy clinical trial processes.
- Potential safety or efficacy concerns with PLENITY or pipeline therapies.
- Changes in reimbursement policies or market dynamics.
Competitive Advantages
- Proprietary biomimicry technology platform.
- Patent protection for PLENITY and pipeline therapies.
- First-mover advantage in the non-systemic weight management market.
- Established relationships with healthcare providers and distributors.
About GLS
Gelesis Holdings Inc., incorporated in 2006 and headquartered in Boston, Massachusetts, is a commercial-stage biotherapeutics company focused on developing novel treatments for obesity and gastrointestinal (GI)-related chronic diseases. The company's core technology revolves around biomimicry, aiming to create therapies that mimic natural biological processes to address the root causes of these conditions. Their flagship product, PLENITY, is an orally administered, non-stimulant, and non-systemic aid for weight management, designed to help individuals manage their weight by increasing satiety and reducing hunger. Beyond PLENITY, Gelesis is developing a pipeline of potential therapies targeting non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes, and functional constipation (GS500). These programs reflect the company's broader strategy to address a range of metabolic and GI disorders with significant unmet medical needs. Gelesis operates primarily in the United States, focusing on direct-to-consumer marketing and partnerships with healthcare providers to promote PLENITY and advance its pipeline programs. The company aims to establish itself as a leader in the development of innovative, non-systemic therapies for chronic diseases related to obesity and GI health.
What They Do
- Develops biomimetic therapies for obesity and GI-related chronic diseases.
- Offers PLENITY, an orally administered aid for weight management.
- Focuses on non-stimulant and non-systemic treatments.
- Targets the genesis of obesity and related disorders.
- Develops pipeline therapies for NAFLD/NASH and type 2 diabetes.
- Offers GS500 for Functional Constipation.
Business Model
- Develops and commercializes proprietary therapies for obesity and GI disorders.
- Generates revenue through sales of PLENITY.
- Partners with healthcare providers and distributors to expand market reach.
- Invests in research and development to advance pipeline programs.
Industry Context
Gelesis Holdings Inc. operates within the biotechnology industry, which is characterized by high innovation, intense competition, and significant regulatory oversight. The market for obesity and GI-related therapies is substantial and growing, driven by increasing prevalence of these conditions globally. Gelesis is positioned as a company focused on non-systemic, biomimetic approaches, differentiating it from traditional pharmaceutical companies that rely on systemic drugs. The company competes with other biotechnology and pharmaceutical companies developing treatments for obesity, diabetes, and GI disorders. The industry is subject to stringent regulatory requirements and lengthy clinical trial processes.
Key Customers
- Individuals seeking weight management solutions.
- Healthcare providers who prescribe or recommend PLENITY.
- Patients with NAFLD/NASH, type 2 diabetes, and functional constipation (future).
Financials
Chart & Info
Gelesis Holdings, Inc. (GLS) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Oct 24, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GLS.
Price Targets
Wall Street price target analysis for GLS.
MoonshotScore
What does this score mean?
The MoonshotScore rates GLS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Yishai Zohar
Chief Executive Officer
Yishai Zohar serves as the Chief Executive Officer of Gelesis Holdings Inc. His background includes extensive experience in the healthcare and pharmaceutical industries, with a focus on commercialization and strategic development. He has held leadership positions at various companies, contributing to the launch and growth of innovative healthcare products. Zohar's expertise spans across marketing, sales, and business development, making him instrumental in guiding Gelesis through its commercial stage.
Track Record: Under Yishai Zohar's leadership, Gelesis has focused on expanding the market reach of PLENITY and advancing its pipeline programs. Key milestones include securing partnerships with healthcare providers and distributors, as well as initiating clinical trials for pipeline therapies. Zohar's strategic decisions have been centered around building a strong commercial foundation for PLENITY and positioning Gelesis as a leader in the non-systemic weight management market.
GLS Healthcare Stock FAQ
What does Gelesis Holdings, Inc. do?
Gelesis Holdings Inc. is a commercial-stage biotherapeutics company focused on developing and commercializing novel therapies for obesity and GI-related chronic diseases. Their lead product, PLENITY, is an orally administered, non-stimulant, and non-systemic aid for weight management. The company's business model revolves around developing proprietary therapies, generating revenue through sales of PLENITY, partnering with healthcare providers and distributors to expand market reach, and investing in research and development to advance pipeline programs targeting conditions like NAFLD/NASH and type 2 diabetes. Gelesis aims to address the root causes of these conditions through its biomimicry technology platform.
What do analysts say about GLS stock?
Analyst coverage of Gelesis Holdings Inc. (GLS) is pending, and consensus estimates are not currently available. Key valuation metrics to consider include the company's market capitalization, P/E ratio, profit margin, and gross margin. Growth considerations include the potential for PLENITY to gain market share in the weight management market, the successful development of pipeline therapies, and strategic partnerships to expand market reach. Investors should conduct their own due diligence and consider the risks and uncertainties associated with investing in a micro-cap biotechnology company.
What are the main risks for GLS?
Gelesis Holdings Inc. faces several risks inherent to the biotechnology industry. These include competition from established pharmaceutical companies, regulatory hurdles and lengthy clinical trial processes, potential safety or efficacy concerns with PLENITY or pipeline therapies, dependence on the success of PLENITY for revenue generation, and the need for additional capital to fund operations and expansion. The company's negative profit and gross margins highlight the financial challenges it faces. Investors should carefully consider these risks before investing in GLS.
What are the key factors to evaluate for GLS?
Gelesis Holdings, Inc. (GLS) currently holds an AI score of 61/100, indicating moderate score. Key strength: Novel biomimicry technology platform.. Primary risk to monitor: Potential: Competition from established pharmaceutical companies with greater resources.. This is not financial advice.
How frequently does GLS data refresh on this page?
GLS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GLS's recent stock price performance?
Recent price movement in Gelesis Holdings, Inc. (GLS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel biomimicry technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GLS overvalued or undervalued right now?
Determining whether Gelesis Holdings, Inc. (GLS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GLS?
Before investing in Gelesis Holdings, Inc. (GLS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending, and the information provided is based on existing data and publicly available sources.
- Analyst consensus and price targets are not currently available.